OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no safety findings, and no treatment-related serious adverse events (SAEs)Exploratory quantitative electrophysiology results suggest OV350 had central activity and spectral power consistent with expected physiological effects of KCC2 modulation; aligned with expected drug exposure in the brainPharmacokinetics for ...

BLOOMINGTON, Ill., Dec. 18, 2025 (GLOBE NEWSWIRE) -- HBT Financial, Inc. (NASDAQ: HBT) (the “Company” or “HBT Financial”) announced today that its Board of Directors has approved a new stock repurchase program (the “Program”) that takes effect upon the expiration of the Company’s current stock repurchase program on January 1, 2026. The Company will not execute additional repurchases under the current program after January 1, 2026. The new Program authorizes the Company to repurchase up to $30 million of its ...

CALGARY, Alberta, Dec. 18, 2025 (GLOBE NEWSWIRE) -- DIRTT Environmental Solutions Ltd. (TSX: DRT; OTCQX: DRTTF) ("DIRTT" or the "Company"), a leader in industrialized construction, announced today that the Toronto Stock Exchange ("TSX") has accepted DIRTT's notice of intention to renew its normal course issuer bid (the "Renewed NCIB") for common shares in the capital of DIRTT ("Common Shares"). The Renewed NCIB is expected to commence on December 22, 2025, following the expiry of the Company's current NCIB ...

The LOI Aligns with Federal Priorities on Fentanyl Crisis, Artificial Intelligence, and Quantum TechnologyORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) ("Nutriband" or the "Company"), a developer of transdermal pharmaceutical products including abuse-deterrent technologies, today announced the signing of a non-binding Letter of Intent ("LOI") with the Qvanta Group of Companies. The Qvanta Group comprises Qvanta LLC and its subsidiaries, Qvanta Foundry LLC and ...

Multi-pillar growth plan focused on vertical expansion, sales and marketing, partnerships, and selective acquisitionsNEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Fusemachines Inc. (“Fusemachines” or the “Company”) (NASDAQ:FUSE), a leading provider of enterprise AI products and services, today outlined its strategic growth priorities, positioning the Company for a pivotal year in 2026, focused on disciplined execution, enterprise ROI, and responsible AI product innovation. After more than a decade of building ...

On track for interim analysis in late January 2026 and topline final results November 2026SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that due to the recent accelerated screening and enrolment in the XanaMIA phase 2b/3 Alzheimer’s disease (AD) trial, the company has randomized and commenced treatment of all participants. This means that topline, final results will be available in November next year Dr Dana Hilt, CMO, commented:“There remains an enormous unmet med ...

Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCApplications for the fellowship are due on February 27, 2026 SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical co ...

New Residual Structure Improves Capital EfficiencyROGERS, Ark., Dec. 18, 2025 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart,” or the “Company”) announced today that it has completed a term securitization transaction involving the issuance of $161.3 million in principal amount of asset-backed notes with a weighted average coupon of 7.02%. The 2025-4 transaction marks another significant milestone for Car-Mart, as it introduces a more efficient deal structure that generates incr ...

WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT. A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days fol ...

Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the dosing of the first patient with SAB-142 in the Phase 2b registrational SAFety and Efficacy of human anti-thymocyte immunoGlobUlin ...